{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:57:56Z","timestamp":1791910676354,"version":"4.3.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Myasthenia gravis (MG) is an autoimmune neuromuscular disorder caused by IgG autoantibodies targeting the neuromuscular junction. Recycling of IgG is mediated by the neonatal Fc receptor (FcRn). Efgartigimod, an Fc fragment of human IgG1, has demonstrated efficacy in MG; however, the clinical characteristics of patients with the highest response remain unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twelve patients with AChR-positive generalized MG were treated with two cycles of Efgartigimod over 1\u202fyear, and nine patients completed a third cycle. Clinical evaluation was conducted using MG-ADL at four time points and QMG at the beginning and end of each cycle. MG-ADL and QMG scores were further subdivided into ocular (O), bulbar (B), and generalized (G) symptom subdomains, and patients were classified as predominantly ocular (pO), bulbar (pB), or generalized (pG) based on symptom prevalence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Significant improvements were observed in MG-ADL and QMG from baseline across all symptom subdomains. Baseline AChR antibody levels correlated with MG-ADL improvement (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.04). Thymectomized patients demonstrated superior outcomes, with MG-ADL improving by 62% versus 22% (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.01) and QMG by 45% versus 3.5% (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.01) during the first two cycles. Patients with pO symptoms responded less to therapy, with generalized symptoms contributing most to the minor response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our findings suggest that patients with high baseline AChR antibody titers, previous thymectomy, and non-ocular symptom predominance respond better to Efgartigimod. These results underscore the need for larger studies to validate these observations and optimize patient selection.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1555068","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T04:10:30Z","timestamp":1746591030000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Real world study in Italian public hospital with Efgartigimod in patients affected by generalized myasthenia gravis: influence of clinical and serological factors"],"prefix":"10.3389","volume":"16","author":[{"given":"Manlio","family":"Sgarzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Paone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Camera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Agazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mazzoleni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Martorana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Alimonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1126\/science.1179220","article-title":"Myasthenia gravis: passive transfer from man to mouse","volume":"190","author":"Toyka","year":"1975","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1229112","DOI":"10.3389\/fneur.2023.1229112","article-title":"FcRN receptor antagonists in the management of myasthenia gravis","volume":"14","author":"Bhandari","year":"2023","journal-title":"Front Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1212\/01.wnl.0000903308.81107.e2","article-title":"Long-term safety, tolerability and efficacy of efgartigimod in patients with generalized myasthenia gravis: interim results of the ADAPT+ study","volume":"99","author":"Howard","year":"2022","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in myasthenia gravis clinical research and care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1212\/01.WNL.0000163988.28892.79","article-title":"Quantitative myasthenia gravis: assessment of responsiveness and longitudinal validity","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00109-008-0366-7","article-title":"Neonatal fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita","volume":"86","author":"Sesarman","year":"2008","journal-title":"J Mol Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e16098","DOI":"10.1111\/ene.16098","article-title":"Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study","volume":"31","author":"Bril","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.2147\/JIR.S455104","article-title":"Therapeutic plasma exchange in AChR-ab positive generalized myasthenia gravis: a real world study about its early response","volume":"17","author":"Chen","year":"2024","journal-title":"J Inflamm Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/ene.15565","article-title":"Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal","volume":"30","author":"Meisel","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/CND.0b013e31828a0090","article-title":"Correlation between acetylcholine receptor antibody levels and thymic pathology in myasthenia gravis: a review","volume":"14","author":"Huang","year":"2013","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/sjopt.sjopt_74_23","article-title":"Eculizumab in myasthenia gravis: a review","volume":"38","author":"Zhou","year":"2024","journal-title":"Saudi J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/sjmms.sjmms_80_22","article-title":"Thymectomy in myasthenia gravis: a narrative review","volume":"10","author":"Aljaafari","year":"2022","journal-title":"Saudi J Med Med Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00401-021-02299-y","article-title":"Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature","volume":"141","author":"Ingelfinger","year":"2021","journal-title":"Acta Neuropathol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s42466-023-00252-w","article-title":"The impact of thymectomy in subgroups of myasthenia gravis patients: a single center longitudinal observation","volume":"5","author":"Menghesha","year":"2023","journal-title":"Neurol Res Pract"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"30649","DOI":"10.1073\/pnas.2007206117","article-title":"Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis","volume":"117","author":"Jiang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1212\/WNL.0000000000004676","article-title":"Myasthenia gravis impairment index: responsiveness, meaningful change, and relative efficiency","volume":"89","author":"Barnett","year":"2017","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.braindev.2014.12.007","article-title":"Reduction in peripheral regulatory T cell population in childhood ocular type myasthenia gravis","volume":"37","author":"Nishimura","year":"2015","journal-title":"Brain Dev"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jneuroim.2013.09.006","article-title":"Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients","volume":"264","author":"Kohler","year":"2013","journal-title":"J Neuroimmunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2024","journal-title":"Front Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1555068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T04:10:31Z","timestamp":1746591031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1555068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":25,"alternative-id":["10.3389\/fneur.2025.1555068"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1555068","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"article-number":"1555068"}}